A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
NCT07020221
This study is recruiting at 13 US sites in 12 states, according to its ClinicalTrials.gov record last updated .
Summary
This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Pancreatic Ductal Adenocarcinoma
- Non Small Cell Lung Cancer
- Colorectal Cancer
- Solid Tumor, Adult
- G12D Mutated KRAS
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Verastem, Inc.
- Last updated on ClinicalTrials.gov
- October 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Cedars-Sinai Medical Center · Los Angeles, CA
Maryland · 1
- Johns Hopkins University · Baltimore, MD
Massachusetts · 1
- Massachusetts General Hospital · Boston, MA
Michigan · 1
- University of Michigan · Ann Arbor, MI
Missouri · 1
- Washington University School of Medicine · St Louis, MO
New York · 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone · New York, NY
Pennsylvania · 1
- Univ of Pennsylvania, Abramson Cancer Center · Philadelphia, PA
Tennessee · 1
- SCRI Oncology Partners · Nashville, TN
Texas · 1
- MD Anderson Cancer Center · Houston, TX
Utah · 1
- Huntsman Cancer Institute · Salt Lake City, UT
Virginia · 2
- University of Virginia · Charlottesville, VA
- Virginia Cancer Specialists · Fairfax, VA
Washington · 1
- Virginia Mason Medical Center · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.